Oral @entity172 cause a decrease of low density lipoprotein @entity165 (LDL-chol.) and, especially an increase of high density lipoprotein @entity165 (HDL-chol.) levels, which both have potentially favorable effects; they also cause a @entity412 level increase, which probably has no clinical relevance except in cases with basal @entity2298 . Transdermal @entity53 causes generally a minor decrease in LDL-chol. and minor increase HDL-chol. levels, with no increase or even decrease in @entity412 levels. The addition of androgenic @entity7828 at conventionally used doses, while not interfering with LDL-chol. variations, causes a HDL-chol. decrease, which contrasts the effect of oral @entity172 and completely reverses the effect of transdermal @entity53 . On the contrary, the addition of a non androgenic @entity1871 does not interfere with any of the @entity172 induced lipid profile modifications.

Lipid profile during hormone replacement therapy: effect of different XXXX ?

@entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen', 'estrogens'] @entity2298 :: ('MESH:D015228', 'Disease') :: ['hypertriglyceridemia'] @entity7828 :: ('MESH:D011372', 'Chemical') :: ['progestins'] @entity53 :: ('MESH:D004958', 'Chemical') :: ['estradiol'] @entity1871 :: ('CHEBI:59826', 'Chemical') :: ['progestin'] @entity412 :: ('CHEBI:17855', 'Chemical') :: ['triglyceride'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']
@entity7828 :: (MESH:D011372,Chemical) :: ['progestins']
